Radius Health Stock Forecast, Price & News

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

Is Radius Health a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health or view top-rated stocks.

How has Radius Health's stock been impacted by Coronavirus (COVID-19)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS shares have decreased by 10.5% and is now trading at $14.38.
View which stocks have been most impacted by COVID-19.

Are investors shorting Radius Health?

Radius Health saw a drop in short interest in November. As of November 15th, there was short interest totaling 2,960,000 shares, a drop of 29.0% from the October 31st total of 4,170,000 shares. Based on an average daily trading volume, of 1,380,000 shares, the days-to-cover ratio is currently 2.1 days. Currently, 6.3% of the company's shares are short sold.
View Radius Health's Short Interest.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Radius Health.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.20. The biopharmaceutical company earned $56.81 million during the quarter, compared to analyst estimates of $61.40 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share.
View Radius Health's earnings history.

What guidance has Radius Health issued on next quarter's earnings?

Radius Health issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210 million-$220 million, compared to the consensus revenue estimate of $242.26 million.

What price target have analysts set for RDUS?

5 brokerages have issued 12 month target prices for Radius Health's stock. Their forecasts range from $16.00 to $33.00. On average, they expect Radius Health's share price to reach $25.00 in the next year. This suggests a possible upside of 73.9% from the stock's current price.
View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts.

Who are Radius Health's key executives?

Radius Health's management team includes the following people:

• George Kelly Martin, President, Chief Executive Officer & Director
• Steven Helwig, CFO, Treasurer & Chief Accounting Officer
• Bruce Mitlak, Chief Medical Officer
• Averi Price, Secretary, Chief Compliance Officer & VP
• Chhaya Shah, Chief Business Officer & Senior Vice President

Who are some of Radius Health's key competitors?

Some companies that are related to Radius Health include PTC Therapeutics (PTCT), OPKO Health (OPK), Aurinia Pharmaceuticals (AUPH), Ligand Pharmaceuticals (LGND), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), ChemoCentryx (CCXI), TG Therapeutics (TGTX), Sage Therapeutics (SAGE), Harmony Biosciences (HRMY), Prothena (PRTA), Emergent BioSolutions (EBS), Nektar Therapeutics (NKTR), Lyell Immunopharma (LYEL) and Indivior (INVVY).
View all of RDUS's competitors.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Bellevue Group AG (16.44%), Rubric Capital Management LP (7.76%), BlackRock Inc. (7.45%), Wellington Management Group LLP (4.67%), Geode Capital Management LLC (1.72%) and Morgan Stanley (0.93%). Company insiders that own Radius Health stock include James George Chopas and Target N V Biotech.
View institutional ownership trends for Radius Health.

Which major investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Russell Investments Group Ltd., Wellington Management Group LLP, New York State Common Retirement Fund, Arrowstreet Capital Limited Partnership, BlackRock Inc., Millennium Management LLC, and Citigroup Inc..
View insider buying and selling activity for Radius Health or view top insider-selling stocks.

Which major investors are buying Radius Health stock?

RDUS stock was purchased by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Bellevue Group AG, Two Sigma Investments LP, Clearline Capital LP, Renaissance Technologies LLC, Summit Global Investments, UBS Group AG, and Granahan Investment Management Inc. MA.
View insider buying and selling activity for Radius Health or or view top insider-buying stocks.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $14.38.

How much money does Radius Health make?

Radius Health has a market capitalization of $680.78 million and generates $238.65 million in revenue each year. The biopharmaceutical company earns $-109.21 million in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 310 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

Where are Radius Health's headquarters?

Radius Health is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701.